Gennaro F. Pagano

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 152 publications

Isavuconazole as primary antifungal prophylaxis in pediatric hematological patients: a clinical and pharmacokinetic analysis.

Isavuconazole as primary antifungal prophylaxis in pediatric hematological patients: a clinical and pharmacokinetic analysis.

Journal: Antimicrobial agents and chemotherapy

Published: June 26, 2026

Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.

Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms.

Journal: Haematologica

Published: February 25, 2026

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Journal: Lancet (London, England)

Published: February 02, 2026

Impact of nutritional source modality on weight loss and BMI reduction after hematopoietic stem cell transplantation.

Impact of nutritional source modality on weight loss and BMI reduction after hematopoietic stem cell transplantation.

Journal: Frontiers in oncology

Published: December 30, 2025

Speech Impairment in Early Parkinson's Disease Is Associated with Nigrostriatal Dopaminergic Dysfunction.

Speech Impairment in Early Parkinson's Disease Is Associated with Nigrostriatal Dopaminergic Dysfunction.

Journal: Journal of clinical medicine

Published: December 11, 2025

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Journal: NPJ Parkinson's disease

Published: August 13, 2025

Translational molecular imaging and drug development in multiple sclerosis.

Translational molecular imaging and drug development in multiple sclerosis.

Journal: Theranostics

Published: June 14, 2025

Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta-Analysis.

Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta-Analysis.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: May 15, 2025

Addressing the need for standardization of symptomatic medication documentation in Parkinson's disease clinical research: A call to action.

Addressing the need for standardization of symptomatic medication documentation in Parkinson's disease clinical research: A call to action.

Journal: Journal of Parkinson's disease

Published: February 20, 2025

Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III.

Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III.

Journal: Journal of Parkinson's disease

Published: February 20, 2025

The "five-star matrix" for patient-centric drug discovery and development in neuroscience.

The "five-star matrix" for patient-centric drug discovery and development in neuroscience.

Journal: Neuron

Published: February 02, 2025

Neuronal α-Synuclein Disease Stage Progression over 5 Years.

Neuronal α-Synuclein Disease Stage Progression over 5 Years.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 26, 2024

Showing 1-12 of 152

Last Updated: 09/26/2026